Literature DB >> 30102655

Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates.

Josefin Koehn1, Jennifer F Iwamoto1, John C Kraft1, Lisa A McConnachie1, Ann C Collier2,3, Rodney J Y Ho1,3,4.   

Abstract

OBJECTIVE: To characterize a drug-combination nanoparticle (DcNP) containing water-insoluble lopinavir (LPV) and efavirenz (EFV), and water-soluble tenofovir (TFV), for its potential as a long-acting combination HIV treatment.
DESIGN: Three HIV drugs (LPV, EFV, TFV) with well established efficacy and safety were coformulated into a single DcNP suspension. Two macaques were administered one subcutaneous injection and drug concentrations in plasma and mononuclear cells (in peripheral blood and lymph nodes) were analyzed over 2 weeks. Pharmacokinetic parameters and cell-to-plasma relationships of LPV, EFV, and TFV were determined.
RESULTS: This three-in-one nanoformulation provided extended concentrations of all drugs in lymph node cells that were 57- to 228-fold higher than those in plasma. Levels of all three drugs in peripheral blood mononuclear cells persisted for 2 weeks at levels equal to or higher than those in plasma.
CONCLUSION: With long-acting characteristics and higher drug penetration/persistence in cells, this three-in-one DcNP may enhance therapeutic efficacy of these well studied HIV drugs due to colocalization and targeting of this three-drug combination to HIV host cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30102655      PMCID: PMC6482845          DOI: 10.1097/QAD.0000000000001969

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  26 in total

1.  Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry.

Authors:  S Colombo; A Beguin; A Telenti; J Biollaz; T Buclin; B Rochat; L A Decosterd
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-05-25       Impact factor: 3.205

2.  A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals.

Authors:  Martin Markowitz; Teresa H Evering; Donald Garmon; Marina Caskey; Melissa La Mar; Kristina Rodriguez; Vincent Sahi; Sarah Palmer; Nicole Prada; Hiroshi Mohri
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

3.  Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues.

Authors:  Courtney V Fletcher; Kathryn Staskus; Stephen W Wietgrefe; Meghan Rothenberger; Cavan Reilly; Jeffrey G Chipman; Greg J Beilman; Alexander Khoruts; Ann Thorkelson; Thomas E Schmidt; Jodi Anderson; Katherine Perkey; Mario Stevenson; Alan S Perelson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

4.  Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.

Authors:  Jennifer P Freeling; Josefin Koehn; Cuiling Shu; Jianguo Sun; Rodney J Y Ho
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

5.  Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.

Authors:  S G Deeks; P Barditch-Crovo; P S Lietman; F Hwang; K C Cundy; J F Rooney; N S Hellmann; S Safrin; J O Kahn
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

6.  Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalities.

Authors:  John C Kraft; Piper M Treuting; Rodney J Y Ho
Journal:  J Drug Target       Date:  2018-02-12       Impact factor: 5.121

7.  Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques.

Authors:  Loren Kinman; Scott J Brodie; Che Chung Tsai; Tot Bui; Kay Larsen; Ann Schmidt; David Anderson; William R Morton; Shiu-Lok Hu; Rodney J Y Ho
Journal:  J Acquir Immune Defic Syndr       Date:  2003-12-01       Impact factor: 3.731

Review 8.  Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.

Authors:  Brian P Kearney; John F Flaherty; Jaymin Shah
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates.

Authors:  Michele Di Mascio; Chang H Paik; Jorge A Carrasquillo; Jin-Soo Maeng; Beom-Su Jang; In Soo Shin; Sharat Srinivasula; Russ Byrum; Achilles Neria; William Kopp; Marta Catalfamo; Yoshiaki Nishimura; Keith Reimann; Malcolm Martin; H Clifford Lane
Journal:  Blood       Date:  2009-05-05       Impact factor: 22.113

10.  Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011.

Authors:  Heather Bradley; H Irene Hall; Richard J Wolitski; Michelle M Van Handel; Amy E Stone; Michael LaFlam; Jacek Skarbinski; Darrel H Higa; Joseph Prejean; Emma L Frazier; Roshni Patel; Ping Huang; Qian An; Ruiguang Song; Tian Tang; Linda A Valleroy
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-11-28       Impact factor: 17.586

View more
  7 in total

Review 1.  The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture.

Authors:  Howard E Gendelman; JoEllyn McMillan; Aditya N Bade; Benson Edagwa; Bhavesh D Kevadiya
Journal:  Trends Microbiol       Date:  2019-04-10       Impact factor: 17.079

Review 2.  Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.

Authors:  Jesse Yu; Qingxin Mu; Millie Fung; Xiaolin Xu; Linxi Zhu; Rodney J Y Ho
Journal:  Pharmacol Ther       Date:  2022-01-06       Impact factor: 13.400

3.  Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles.

Authors:  Simone Perazzolo; Danny D Shen; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2021-10-19       Impact factor: 3.784

4.  Towards COVID-19 Prophylaxis: An AIDS Preclinical Research Perspective.

Authors:  Michele Di Mascio
Journal:  Cancer Stud Ther       Date:  2020-07-19

5.  Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules.

Authors:  Jesse Yu; Qingxin Mu; Simone Perazzolo; James I Griffin; Linxi Zhu; Lisa A McConnachie; Danny D Shen; Rodney Jy Ho
Journal:  Pharm Res       Date:  2020-09-23       Impact factor: 4.200

6.  A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S.

Authors:  Jane M Simoni; Kenneth Tapia; Sung-Jae Lee; Susan M Graham; Kristin Beima-Sofie; Zahra H Mohamed; Joan Christodoulou; Rodney Ho; Ann C Collier
Journal:  AIDS Behav       Date:  2020-04

7.  Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.

Authors:  Qingxin Mu; Jesse Yu; James I Griffin; Yan Wu; Linxi Zhu; Lisa A McConnachie; Rodney J Y Ho
Journal:  PLoS One       Date:  2020-03-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.